Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$436,259
+$350,437 QoQ
Shares Held
8,018
+300.7% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
#455
of 756 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MCGUIRE CAPITAL ADVISORS INC holds $759,836 across 23 Biotechnology names. EXEL ranks #1 (57.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
8,018 | $436,259 | |
| 2 | INCY |
Incyte Corp
|
1,166 | $132,177 | |
| 3 | PTCT |
Ptc Therapeutics, Inc.
|
1,601 | $130,593 | |
| 4 | ARQT |
Arcutis Biotherapeutics, Inc.
|
510 | $13,372 | |
| 5 | EDSA |
Edesa Biotech, Inc.
|
1,500 | $12,195 | |
| 6 | IBRX |
ImmunityBio, Inc.
|
900 | $7,879 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
24 | $5,874 | |
| 8 | TGTX |
Tg Therapeutics, Inc.
|
65 | $3,571 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $436,259 | 8,018 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $85,822 | 2,001 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $22,879 | 522 | Shares | Sole | 2026-02-19 | |
| No filing history on record for this holder in this stock. | ||||||